Hepatitis B
EASL 2014: Prolonged Pegylated Interferon + Tenofovir Does Not Prevent Hepatitis Delta Relapse
- Details
- Category: Hepatitis Delta (HDV)
- Published on Friday, 18 April 2014 00:00
- Written by Liz Highleyman
Treating hepatitis B patients with hepatitis delta virus (HDV) coinfection using pegylated interferon plus tenofovir (Viread) for 96 weeks may reduce HDV viral load, but side effects are frequent and it did not significantly improve the likelihood of hepatitis B surface antigen (HBsAg) reduction, according to a report at the 49thEASL International Liver Congress last week in London.
EASL 2014: Adding Interferon to Antivirals May Improve Response for Hepatitis B Patients
- Details
- Category: HBV Treatment
- Published on Monday, 14 April 2014 00:00
- Written by Liz Highleyman
Adding pegylated interferon to entecavir (Baraclude) led to greater hepatitis B virus (HBV) viral load decline and higher likelihood of serological response in HBeAg positive chronic hepatitis B patients, as did added interferon after long-term nucleoside therapy, but adding interferon after a only short course of antivirals did not improve response, according to a set of studies presented at the 49th EASL International Liver Congress last week in London.
Increased Distance Reduces Likelihood of Liver Transplant
- Details
- Category: Liver Transplant - HBV
- Published on Friday, 04 April 2014 00:00
- Written by Liz Highleyman
Living and receiving health care further away from a transplant center was associated with lower chances of being wait-listed for or receiving a liver transplant, according to a study of U.S. veterans described in the March 26 edition of JAMA.
EASL 2014: New Research Sheds Light on Liver Cancer Diagnosis, Staging, and Treatment
- Details
- Category: Liver Cancer/HCC
- Published on Monday, 14 April 2014 00:00
- Written by EASL
Dramatic regional differences in survival rates for people with hepatocellular carcinoma (HCC) are largely attributable to varying national policies regarding screening and treatment, according to study findings presented at the 49thEASL International Liver Congress last week in London. Related research showed that percutaneous radiofrequency ablation is effective for treating single liver cancer tumors.
Updated Entecavir Label Expands Indication for Children with Hepatitis B
- Details
- Category: HBV Treatment
- Published on Tuesday, 25 March 2014 00:00
- Written by FDA
The U.S. Food and Drug Administration (FDA) last week approved new label information for entecavir (Baraclude), a nucleoside analog used to treat chronic hepatitis B virus (HBV) infection. The revised label expands the indication for pediatric use by children age 2 years and up.
EASL 2014: International Liver Congress Starts this Week in London
- Details
- Category: HBV Treatment
- Published on Tuesday, 08 April 2014 00:00
- Written by HIVandHepatitis.com
The European Association for the Study of the Liver's International Liver Congress (EASL 2014) takes place April 9-13 at the ExCel Centre in London. The annual conference is one of the key annual scientific meetings covering viral hepatitis and its complications. Also on Thursday, the World Health Organization (WHO) will release new global guidelines for hepatitis C.
New Guidelines for Hepatitis B Screening
- Details
- Category: HBV Testing & Diagnosis
- Published on Friday, 14 February 2014 00:00
- Written by HIVandHepatitis.com
U.S. Preventive Services Task Force this week released updated guidelines for hepatitis B virus (HBV) screening for adults. The draft recommendations call for screening of high-risk individuals including people with HIV, gay men, people who inject drugs, and people from parts of the world where hepatitis B is common.
U.S. Government Releases Updated Viral Hepatitis Action Plan
- Details
- Category: HBV Policy & Advocacy
- Published on Tuesday, 08 April 2014 00:00
- Written by HIVandHepatitis.com
On April 3 the federal government released its latest 3-year update to the Action Plan for the Prevention, Care and Treatment of Viral Hepatitis (initially launched in 2011), which provides a framework for strengthening the nation's response to hepatitis B and C.
Can Coffee Help Prevent Liver Fibrosis?
- Details
- Category: Fibrosis & Cirrhosis
- Published on Friday, 07 February 2014 00:00
- Written by Liz Highleyman
There is good evidence that coffee has a beneficial effect in people at risk for liver fibrosis and there are plausible biological mechanisms to explain why, according to an editorial in the January 27 advance online edition of Hepatology. However, the amount needed to see such an effect may be too high for many people to tolerate, they cautioned.
More Articles...
- Chronic Hepatitis B Treatment Guidelines
- Monitoring Inactive Hepatitis B Is Cost-effective but Must Increase to Improve Survival
- CDC Updates Guidance for Hepatitis B Vaccination of Health-care Providers
- Adding Pegylated Interferon to Antivirals for Hepatitis B May Lead to HBsAg Loss
- Hepatitis B and C Reduce Survival by More than 20 Years
Web Design and Development by